Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Sarcoma × Clear all

Status

Completed 602 Recruiting 226 Terminated 145 Unknown 133 Active not recruiting 94 Withdrawn 44 Not yet recruiting 36 Enrolling by invitation 8 No longer available 5 Available 5 Suspended 4 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Recurrence 11 Carcinoma, Non-Small-Cell Lung 9 Neoplasms 8 Prostatic Neoplasms 7 Multiple Myeloma 6 Breast Neoplasms 5 Small Cell Lung Carcinoma 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large B-Cell, Diffuse 3 Lung Neoplasms 3 Leukemia, Myeloid, Acute 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Lambert-Eaton Myasthenic Syndrome 3 HER2-positive Breast Cancer 3 Thyroid Neoplasms 2 Pheochromocytoma 2 Paraganglioma 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neuroendocrine Tumors 2 Myasthenic Syndromes, Congenital 2 Lymphoma 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia 2 Head and Neck Neoplasms 2 Glioma 2 Colonic Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Transitional Cell 2 Carcinoma, Medullary 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03994627 2024-12-16

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Eli Lilly and Company

Approved for marketing

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡